AIM AIM ImmunoTech

AIM ImmunoTech Provides First Quarter 2021 Business Update

AIM ImmunoTech Provides First Quarter 2021 Business Update

OCALA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021.   

  • As of March 31, 2021, AIM had cash, cash equivalents and marketable securities of $63.6 million, compared to $54.4 million as of December 31, 2020.



  • Research and development expenses for the three months ended March 31, 2021 were $1.4 million, compared to $0.9 million for the three months ended March 31, 2020.



  • General and administrative expenses for the three months ended March 31, 2021 were $2.1 million, compared to $2.3 million for the three months ended March 31, 2020.



  • The net loss from operations for the three months ended March 31, 2021 was $3.6 million, or $0.08 per share, compared to $3.8 million, or $0.22 per share, for the three months ended March 31, 2020.

“I’m extremely proud of the progress we have made throughout the first quarter,” commented Thomas K. Equels, CEO of AIM ImmunoTech. “We have established a strong foundation of pre-clinical and clinical data with respect to the development of therapeutics aimed to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. With our solid financial standing, we intend to execute on our corporate strategy and aggressively move forward with our clinical programs that address critical unmet medical needs. We have reached many important milestones, are encouraged by the outlook for AIM and look forward to providing meaningful updates along the way.”

Please refer to the full 10-Q for complete details. Additionally, please refer to AIM’s most recent for updates on ongoing clinical studies.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of

therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Investor Relations Contact:

Crescendo Communications, LLC

Phone: 212-671-1021

Email:

AIM ImmunoTech Inc

Phone: 800-778-4042

Email:



EN
18/05/2021

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the...

February 12, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Ev...

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that of AIM, will participate in a  on Thursday, February 19, 2026, at 4:00 PM ET. Equels will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing  in col...

February 12, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech Announces Commencement of Rights Offering OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the “Rights Offering”).  Pursuant to the Rights Offering, the Company is distributing to all holders of record of ...

February 11, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series ...

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today that it will participate in the being held virtually February 10-11, 2026. As part of the event, of AIM, will provide a corporate overview and business outlook and will focus on AIM’s strategic emphasis on pancreatic cancer. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:40 PM ESTP...

February 6, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress fro...

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responses OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZenec...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch